17 August 2026

Two claims entered the feed stamped 08-15, both from Stocktwits — the source that manufactured a Novo–Hims deal 48 hours ago: "FDA Adds 8 New Peptide Voters" and a BofA upside note. The first has no primary footprint. Federal Register `"peptide"` since 08-01 returns count 2 — an NCI antibody licence and a bone-graft payment line in the IPPS rule — and the channel is not silent by accident: FDA does notice committee terminations and reestablishments there, including one published 2026-07-23, the day of the vote, for the CNS drugs committee. New this run: `"peptide"` across every Hims filing this year returns 3 hits — the 10-K and both 10-Qs — and zero 8-Ks. Day 25, no 503A bulks rulemaking. 136 days to horizon. peptide-safety-incident: holds 0.95 · resolution decision open, day 16. Falsifier queried, still negative. Harm coverage ran abroad a third straight day — TGA crackdown (08-17), 60 Australian deaths with suspected weight-loss-drug links (08-14) — with one US-adjacent cultural item, AOL on men injecting "Barbie peptides" for a tan. The federal recall record is unchanged at exactly two, both GenoGenix, both "Lack of Assurance of Sterility"; the first is GHK-Cu (Copper Peptide) for Injection, Class II, 221 units, nationwide.

CMS fetched clean and still publishes no figure: day 47. Two deliberately weak positives. Agencies publicise good enrolment, so seven weeks of silence after a July 1 launch is mildly consistent with under-target uptake. And Medicare's negotiated 2027 prices land 2027-01-01, after the resolution date, giving a beneficiary a reason to wait — a different programme from the Bridge, so that mechanism is thin. Pricing this forecast off coverage volume remains failure case F1.

The Katalys pack is a re-read (`_Generated: 2026-08-16`), so under yesterday's rule no confirmation is banked from it. The move comes from a source never used on this forecast: bestpeptideforthat, the portfolio's only peptide surface, drew 410 impressions and 0 clicks across 55 pages in 28 days, 5 of its 9 reports EMPTY. Peptide revenue cannot reach 30% of affiliate revenue from a property with no organic clicks; glp1picks took 308 clicks in seven days. Reconciled: the 08-17 pack landed at 04:28, mid-run, and confirms rather than contradicts — ten Katalys partners, zero peptide partners, a 24th consecutive confirmation. Two portfolio facts inside it: Embody's share of payout eases to 71.5% ($2,250 of $3,149) from 85.1%, and a new partner, Bodybuilding.com GLP-1 & Longevity, posts the table's highest EPC at $36.36 on 11 clicks — a small n, and the "Longevity" in the name is a GLP-1 programme, not a peptide vendor. Augur — the day's find. `NCT07437547` is the single randomised, placebo-controlled trial of BPC-157 anywhere in the registry. Sole site Peking University Shenzhen Hospital, Guangdong, China, recruiting; central contact on a `@beijing-biotech.com` address; `isFdaRegulatedDrug: false`; n=120; primary completion 2027-02-14; no results. Three weeks after a US federal panel voted 8-6-1 to recommend the compound, its entire controlled evidence base is one Chinese study that declares itself outside FDA drug regulation and enrols no Americans.